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Abstract
Despite concerted efforts to eliminate malaria, it remains a major global cause of morbidity and 
mortality with over 200 million annual cases. Significant gains have been made, with the annual 
global malaria incidence and mortality halving over the past twenty years, using tools such as 
long-lasting insecticide-treated bednets and artemisinin-based therapies. Malaria is also a 
significant cause of life-threatening imported infection in the UK. It is vital for front line clinical 
staff involved in the assessment of acutely ill patients to be aware of the need for early 
diagnostic testing, malaria epidemiology, markers of severe infection, and developments in 
antimalarial treatments to optimize patient management. The difference between a good and 
poor outcome is early diagnosis and treatment. Many of the challenges faced in the quest for 
global eradication, such as availability of appropriate diagnostic tests, and drug and insecticide 
resistance could also have future implications for imported malaria.
Key points
1. Malaria must be considered in all patients with history of fever who visited malaria 
endemic areas within the preceding year.
2. Blood film microscopy remains the gold standard for malaria diagnosis, with rapid 
diagnostic tests serving as useful adjuncts.
3. Intravenous artesunate is the drug of choice for patients with severe falciparum malaria; 
oral artemisinin-based combinations are recommended for uncomplicated malaria.
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4. Malaria elimination is being pursued in several countries with the eventual aim of global 
eradication, but despite successes it remains common especially in Africa. 
5. Malaria science is advancing rapidly including a falciparum malaria vaccine and a new 
drug for vivax malaria relapse being licensed in the last two years.  
Introduction
Malaria, caused by Plasmodium parasites and transmitted by anopheline mosquitoes, remains a 
major cause of global morbidity and mortality with an estimated 216 million cases in 2016 and 
445 000 deaths.1 Recent efforts to control and eventually eliminate malaria have reduced the 
disease burden in several countries, but it remains an important cause of imported infection in 
the UK, with 1792 cases reported in 2017, causing 6 deaths. Plasmodium falciparum  accounts 
for 81% of UK infections.2 During the 20th century malaria was eliminated from many temperate 
regions, including England, but remains endemic to 91 countries worldwide.1 Several species of 
parasite cause human malaria (P. falciparum, P.vivax, P.ovale curtisi, P. ovale wallikeri, and P. 
malariae), with the zoonotic P. knowlesi an important human pathogen in parts of southeast 
Asia.
Key Points for UK Clinicians
Updated UK malaria treatment guidelines were published in 2016.3 Here we highlight key 
messages and recent changes.
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Clinical presentation.
The incubation period and clinical presentation of malaria are highly variable and non-specific, 
and missed or late diagnosis is life-threatening. Symptoms begin during the blood stage of 
infection (Figure 1). Malaria should be considered in any patient presenting with fever or 
history of fever up to 1 year after returning from the tropics, or sometimes longer especially if 
P. vivax infection is a possibility. Common symptoms of uncomplicated malaria include fevers, 
chills, muscle and joint aches, headache. The key to diagnosis is prompt laboratory malaria 
testing. It is not possible to diagnose malaria based on clinical features alone. Severe malaria 
has a clearly defined set of clinical and laboratory criteria which must be systematically 
considered (Table 1); if patients have any of these they will need parenteral treatment. Elderly 
patients, and those who are pregnant are at particular risk of complications from malaria.4
Diagnosis.
Examination of blood films remains the gold standard for malaria diagnosis. Microscopy 
confirms or excludes malaria, identifies malaria species, and determines the density of 
parasitaemia. Rapid diagnostic tests (RDTs) are an additional investigation, and detect the 
presence of malaria antigens in a “dipstick” format.5 RDTs are a useful adjunct, but not a 
replacement for blood film microscopy. Once malaria is diagnosed treatment should start 
without delay.
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Malaria is a notifiable disease in the UK. Blood films should be sent for confirmation to the 
Malaria Reference Laboratory (MRL) in England and Wales, and The Scottish Parasite and 
Diagnostic Reference Laboratory in Scotland. 
Artemisinins
Artemisinin derivative drugs are central to the management of malaria.6 Parenteral artesunate 
should be first line treatment in all patients diagnosed with severe malaria including children 
and all trimesters of pregnancy. Artesunate has been shown to reduce mortality compared to 
quinine in two large trials (SEAQUAMAT in South East Asia,7 and AQUAMAT in Africa).8 
Artesunate does not hold a UK license, but is available in many UK infectious diseases units and 
can be urgently supplied from specialist tropical medicine centres in London and Liverpool 
(contact details below). Malaria is life-threatening, and can progress rapidly, so if artesunate is 
not immediately available, treatment of severe malaria with IV quinine should not be delayed 
whilst artesunate is being obtained. If you are not experienced in managing severe malaria we 
recommend getting advice from a specialist centre for the complications including cerebral 
malaria, acute lung injury and renal failure, but in all situations prompt administration of high 
dose intravenous artesunate (or quinine if not available) is the most important intervention. 
For non-severe malaria, oral artemisinin combination therapies (ACTs) are the treatment of 
choice. Two ACTs are licensed for use in the UK, artemether-lumefantrine (Riamet®) and 
dihydroartemesinin-piperaquine (Eurartesim®); the former more commonly stocked by UK 
pharmacies. 
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Non-Falciparum Malaria
Non-falciparum malaria (vivax, ovale, malariae) can be treated with ACT or, if ACT is 
unavailable, with chloroquine. These infections are usually treated with oral drugs as 
outpatients, but if signs of severity or vomiting are present, admission for parental treatment is 
appropriate. Deaths do occur, especially in the elderly.9 In P. vivax and P. ovale spp. malaria it is 
important to ensure eradication of hypnozoites in the liver to prevent relapse of infection. 
Primaquine is the current hypnozoitocidal drug, with 14 days of follow on treatment after the 
schizonticide recommended to required prevent relapse. Patients may fail to complete the full 
14-day primaquine course. Primaquine treatment is complicated by haemolysis risk in patients 
with G6PD deficiency which can be severe, and G6PD screening is required before primaquine 
can be given. A new drug, tafenoquine, has been given a license for vivax relapse by the FDA in 
2018. Tafenoquine is a single dose radical cure but has the same risks with G6PD deficiency as 
primaquine, so may increase adherence but does not reduce the safety risk. 
The Global Outlook: new directions
Malaria Eradication, and its implications for imported infection.
Significant progress towards local elimination of malaria has been made over the past 20 years 
with the aim of eventual global eradication. Whilst control has improved substantially in some 
countries the slowest progress is in some of the highest transmission settings in sub-Saharan 
Africa and significant numbers of imported cases can be expected from Africa for the 
foreseeable future.1 
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The primary target for malaria elimination is P. falciparum. As transmission falls within a 
population there may be an overall decrease in the prevalence of partial immunity to 
falciparum malaria, and a consequent increase in the risk of severe disease in individuals who 
are infected. Assuming adults from Africa with imported malaria are semi-immune is 
increasingly unlikely to be a safe clinical approach. Hypnozoite-mediated relapse of vivax 
malaria is difficult to prevent, so an epidemiological shift towards a higher proportion of P. 
vivax infections can occur as P. falciparum infections become less prevalent. This is already 
apparent in parts of Asia and Latin America.  
Vector Control
The biggest impact on malaria incidence in high transmission settings has probably come from 
Long-Lasting Insecticide treated Nets (LLINs). The widespread distribution and increasing 
acceptance of LLINs has had a dramatic influence on malaria morbidity and mortality, but 
increasingly prevalent pyrethroid resistance in Anopheles mosquitoes is a potential threat to 
continued success which is difficult to combat.10 There is a risk that protection of travellers 
under LLINs will decrease. 
Drug Resistance
Like other micro-organisms, Plasmodium is capable of developing resistance under selective 
drug pressure. In the 1990s, the global spread of resistance to chloroquine and sulfadoxine-
pyramethamine lead to increased morbidity and mortality, particularly in African children.11 The 
emergence and spread of artemisinin resistance in South-East Asia over the past decade is now 
Page 6 of 16
https://mc04.manuscriptcentral.com/clinmed
Clinical Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
7
a major cause for concern and a serious potential threat to global health, given the reliance on 
artesunate for severe disease, and ACTs for non-severe malaria. Artemisinin resistance causes 
delayed parasite clearance and post-treatment gametocytaemia, suggesting increased potential 
for onward transmission.12 At present, proven artemsinin resistance is confined to Asia. The 
spread of artemisinin resistance into areas of higher endemicity, particularly certain areas in 
sub-Saharan Africa, would represent a major setback for malaria control. In the UK, there is 
limited but emerging evidence for treatment failure of non-severe imported malaria with 
artemether-lumefantrine.13 We need to remain vigilant for signs of reduced artemether-
lumefantrine efficacy among imported cases of malaria. A shift to the more widespread use of 
alternative ACTs such as dihydroartemisinin-piperaquine in the future may be required.
Diagnostic Challenges in Elimination and Imported Malaria.
Case finding is key both to a successful elimination programme and to diagnosing malaria in 
low-endemic settings including imported malaria to non-endemic countries. Specialist 
parasitology laboratories have a very high sensitivity for clinical malaria, but this is not always 
shared by routine laboratories. We need better tests for identifying low parasite density 
infections (common in imported malaria), asymptomatic patients at risk of relapse with P. vivax 
and P. ovale spp., methods to identify pockets of high transmission where overall malaria 
incidence is falling, and means to identify the last few cases at the end of an elimination 
campaign. These challenges would all benefit from more sensitive point of care tests.14 A 
concern identified over recent years is the emergence of strains of P. falciparum in the 
Americas and Africa with deletions in the PfHRP2 gene leading to false negative RDTs.15 It is not 
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yet clear how widespread this is, but in malaria imported from some countries the proportion 
may be high enough to limit the usefulness of HRP2-only RDTs if used as the only diagnostic 
test. This is a persuasive reason to maintain malaria microscopy.
Vaccine Development
An effective malaria vaccine would be transformational but has proved difficult to achieve. 
Many immunogens have been tried including whole irradiated parasites, viral vectors encoding 
malaria peptides, and protein subunits.16 The protein-in-adjuvant RTS,S/AS01 vaccine is the 
most advanced candidate, has been licensed for use in children in endemic countries and has 
been shown to elicit modest and relatively short-lived efficacy in phase 3 evaluation.17 A more 
substantial efficacy was observed in older children (36·3% in 5-17 month olds). Whilst it may 
play an important role in control in some endemic settings, the current vaccine is unlikely to 
shift the epidemiology in most countries of relevance to travellers, or to be effective as a 
travellers vaccine against malaria. 
Conclusions
Malaria remains an important cause of life-threatening imported infection in the UK; prompt 
diagnosis with microscopy and treatment are essential. Recent scientific developments 
including new drugs, diagnostics, a vaccine and initiatives for local elimination of malaria are 
important for control but will have limited impact on imported malaria in the next few years.
Useful contacts
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Malaria Reference Laboratory https://www.gov.uk/ government/publications/malaria-
reference-laboratory- mrl-user-handbook.
Scottish Parasite and Diagnostic Reference Laboratory
http://www.nhsggc.org.uk/about-us/professional-support- sites/scottish-microbiology-
reference-laboratories/ scottish-parasite-diagnostic-reference-laboratory/
Hospital for Tropical Diseases, UCH, London. 020 3456 7890.
Tropical and Infectious Disease Unit, Royal Liverpool University Hospital. 0151 706 2000.
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Major features of severe or complicated falciparum malaria in adults.
Cerebral involvement: Impaired consciousness, seizures, neurological signs
Pulmonary oedema, acute respiratory distress syndrome (ARDS)
Renal impairment (oliguria <0.4 ml/kg bodyweight per hour or creatinine >265 mmol/l)
Metabolic & Lactic Acidosis (pH < 7.3).
Hypoglycemia (<2.2 mmol/l).
Anaemia (Haemoglobin ≤80 g/L).
Spontaneous bleeding/disseminated intravascular coagulation.
Hypovolaemia/Shock (BP < 90/60 mmHg).
Haemoglobinuria (without G6PD deficiency).
Parasitaemia >10% (In the UK a parastitaemia of >2% or ≤2% with schizonts present 
indicates potentially severe malaria, and is an indication for parenteral treatment)
Pregnancy: Malaria can be more severe in pregnancy. Early consultation with a specialist 
unit should be made, and parenteral therapy should be considered.
Table 1: Major clinical and laboratory features of severe malaria
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Figure 1 legend:
The malaria parasite life cycle in humans begins when a malaria-infected female Anopheles 
mosquito takes a blood meal (1). Sporozoites in the mosquito salivary glands are inoculated 
into the human host. The sporozoites travel via the blood to the liver in a matter of minutes, 
where they infect hepatocytes and mature into schizonts over days to weeks (2). This stage is 
asymptomatic. In P. vivax and P. ovale infection, a dormant stage (hypnozoites) can persist in 
the liver and cause relapses by invading the bloodstream weeks, or even years later. Mature 
hepatic schizonts rupture and release merozoites which infect erythrocytes in the peripheral 
blood stream. This marks the start of the blood stage of infection, during which the clinical 
manifestations of malaria occur (3). The parasites mature within the erythrocytes into ring 
stage trophozoites and then into schizonts, which rupture releasing more merozoites and 
allowing the blood stage cycle to begin again. Some parasites differentiate into sexual 
erythrocytic stages (gametocytes) which are ingested by an Anopheles mosquito during a blood 
meal (4). The gametocytes mature in the mosquito through the sporogonic cycle, ultimately 
resulting in infective sporozoites in the salivary glands in preparation for inoculation into a new 
human host.
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SAQs
1. Which of the following species of malaria is associated with the majority of deaths, both 
globally, and in the UK?
a. P.ovale
b. P. malariae 
c. P.vivax, 
d. P. falciparum
e. P. knowlesi
Correct answer d. 
P.falciparum accounts for nearly all malaria deaths worldwide. Severe disease and death can 
occur with other species, but is rare.
 
2. A 34 year old male patient is brought to A&E having returned from visiting friends and 
relatives in Burkina Faso 5 days previously. He is drowsy with a GCS of 10. He has a 
temperature of 38.9°C, blood pressure of 100/60, respiratory rate of 26. Bloods show an 
Hb of 109 g/dL, Plts 93, WBC 2.8, Creatinine 183 mol/l), PaO2(Air) 9.5kpa, pH 7.25. Blood 
film shows early and late trophozoites of P. falciparum with 12% of RBCs parasitised. What 
antimalarial should he receive?
a. IV Quinine
b. Dihydroartemsinin-piperaquine (Euartesim®)
c. Tafenoquine
d. IV Artesunate
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e. Atovaquone-proguanil (Malarone®)
Correct answer d. 
This patient has severe malaria and should receive IV artesunate. IV Quinine should be used if 
IV artesunate is not available. 
3. Which of the following is a potential sign of severe malaria in adults?
a. Platelets below 90 x 109 /L
b. Temperature >38.7 oC
c. Haemoglobin 10.1 g/Dl 
d. Parasite count 1.3% of red cells parasitized. 
e. Glasgow coma scale 10.
Correct answer e.
Please refer to Table 1 for an outline of the features of severe malaria.
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The malaria parasite life cycle in humans begins when a malaria-infected female Anopheles mosquito takes a 
blood meal (1). Sporozoites in the mosquito salivary glands are inoculated into the human host. The 
sporozoites travel via the blood to the liver in a matter of minutes, where they infect hepatocytes and 
mature into schizonts over days to weeks (2). This stage is asymptomatic. In P. vivax and P. ovale infection, 
a dormant stage (hypnozoites) can persist in the liver and cause relapses by invading the bloodstream 
weeks, or even years later. Mature hepatic schizonts rupture and release merozoites which infect 
erythrocytes in the peripheral blood stream. This marks the start of the blood stage of infection, during 
which the clinical manifestations of malaria occur (3). The parasites mature within the erythrocytes into ring 
stage trophozoites and then into schizonts, which rupture releasing more merozoites and allowing the blood 
stage cycle to begin again. Some parasites differentiate into sexual erythrocytic stages (gametocytes) which 
are ingested by an Anopheles mosquito during a blood meal (4). The gametocytes mature in the mosquito 
through the sporogonic cycle, ultimately resulting in infective sporozoites in the salivary glands in 
preparation for inoculation into a new human host. 
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